| Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share |
The “Net loss per share
- attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders
- basic and diluted” - for the respective periods indicated - is as follows:
| |
|
|
|
| |
|
Year Ended December 31, |
|
| |
|
2020 |
|
|
2019 |
|
| Numerator |
|
|
|
|
|
|
|
|
| Net loss - before noncontrolling interest |
|
$ |
(35,888 |
) |
|
$ |
(17,268 |
) |
| Net loss attributable to noncontrolling interest |
|
|
1,612 |
|
|
|
811 |
|
| Net loss - as reported, attributable to PAVmed Inc. |
|
$ |
(34,276 |
) |
|
$ |
(16,457 |
) |
| |
|
|
|
|
|
|
|
|
| Series B Convertible Preferred Stock dividends – earned(1) |
|
$ |
(287 |
) |
|
$ |
(270 |
) |
| |
|
|
|
|
|
|
|
|
| Net loss attributable to PAVmed Inc. common stockholders |
|
$ |
(34,563 |
) |
|
$ |
(16,727 |
) |
| |
|
|
|
|
|
|
|
|
| Denominator |
|
|
|
|
|
|
|
|
| Weighted average common shares outstanding, basic and diluted(2) |
|
|
47,432,115 |
|
|
|
30,197,458 |
|
| |
|
|
|
|
|
|
|
|
| Loss per share |
|
|
|
|
|
|
|
|
| Basic and diluted |
|
|
|
|
|
|
|
|
| Net loss - as reported, attributable to PAVmed Inc. |
|
$ |
(0.72 |
) |
|
$ |
(0.54 |
) |
| Net loss attributable to PAVmed Inc. common stockholders |
|
$ |
(0.73 |
) |
|
$ |
(0.55 |
) |
|
| Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share |
The common stock equivalents
have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive,
are as follows:
| |
|
December 31, |
|
| |
|
2020 |
|
|
2019 |
|
| PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards |
|
|
8,215,195 |
|
|
|
5,903,529 |
|
| Unit purchase options - as to shares of common stock |
|
|
53,000 |
|
|
|
53,000 |
|
| Unit purchase options - as to shares underlying Series Z Warrants |
|
|
53,000 |
|
|
|
53,000 |
|
| Series Z Warrants |
|
|
16,814,939 |
|
|
|
16,815,039 |
|
| Series W Warrants |
|
|
381,818 |
|
|
|
381,818 |
|
| Series B Convertible Preferred Stock(3) |
|
|
1,228,075 |
|
|
|
1,158,209 |
|
| Total |
|
|
26,746,027 |
|
|
|
24,364,595 |
|
| (1) |
The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented. |
| |
|
| (2) |
Basic weighted-average number of shares of common stock outstanding for the years ended December 31, 2020 and 2019 include the shares of the Company issued and outstanding during the years ended December 31, 2020 and December 31, 2019, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. |
| |
|
| (3) |
If converted, at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in a corresponding number of additional outstanding shares of common stock of the Company. |
|